ER+ Breast Cancer, HER2-negative Breast Cancer
Conditions
Brief summary
Detection of molecular relapse with circulating tumour DNA analysis can identify which patients with ER positive breast cancer are relapsing on adjuvant endocrine therapy. This trial will aim to demonstrate that palbociclib and fulvestrant, can defer or prevent relapse in patients with ctDNA detected molecular relapse. The TRAK-ER trial will have two phases, a ctDNA surveillance phase and a randomised therapy trial in patients with positive ctDNA. The TRAK-ER trial will establish a ctDNA screening programme for patients with ER positive breast cancer receiving adjuvant endocrine therapy with at least a further three years of standard adjuvant endocrine therapy planned. Patients recruited into the TRAK-ER study will have high-risk clinical features to identify patients at higher risk of future relapse. ctDNA assays will be used to identify which people are at very high risk of relapse (i.e. those with a positive ctDNA result), and randomise this high risk population between standard endocrine therapy versus palbociclib plus fulvestrant for up to two years.
Detailed description
The TRAK-ER trial is a multi-centre, randomised, open-label trial in patients with early stage oestrogen reception positive (ER+) human epidermal growth receptor-2 negative (HER2-) breast cancer, whom have detectable circulating DNA (ctDNA) but no overt macroscopic disease on imaging. TRAK-ER aims to demonstrate that fulvestrant plus palbociclib improves relapse free survival compared to standard endocrine therapy in this patient group. Despite current treatment, patients with ER+HER2- breast cancer are considered high-risk of distant recurrence for more than the first two decades after initial diagnosis. ctDNA analysis provides a non-invasive, serial source of tumour material which can monitor tumour dynamics and detect molecular relapse. TRAK-ER will be split into two phases, the first surveillance phase aims to investigate the use of ctDNA to identify and predict the risk of molecular relapse in early ER+/HER2- breast cancer patients whom are receiving adjuvant endocrine therapy with no overt macroscopic disease on imaging. Using ctDNA assays, patients enrolled on TRAK-ER will receive ctDNA testing on a three-monthly basis for up to three years. In the instance where ctDNA is detected, imaging will determine whether overt disease is present. If a patient had a positive ctDNA detection and no macroscopic disease on the staging scan, the patient will be randomised to one of the treatment groups in the second phase of TRAK-ER, the treatment phase. The treatment phase of TRAK-ER will be a randomised, open-label study which aims to determine whether fulvestrant plus palbociclib (intervention arm) improves relapse free survival compared to standard endocrine therapy (control arm) in patients carried through from the surveillance phase. Patients on each arm will receive treatment (fulvestrant plus palbociclib or standard endocrine therapy) for up to 24 months. Six monthly imaging will determine the presence of macroscopic disease. If macroscopic disease is observed, the patient will discontinue TRAK-ER treatment and commence standard therapy outside of the TRAK-ER trial.
Interventions
Palbociclib Tablets, 125 mg orally once daily, beginning on Cycle 1, on Days 1-21 of each 28-day cycle.
Fulvestrant Intramuscular injections, 500 mg as two injection of 250mg fulvestrant in 5ml solution at each visit. No fulvestrant dose reductions are permitted. Administered on days 1, 15 (plus or minus 3 days), 29 (plus or minus 3 days), and every 28 (plus or minus 3 days) days thereafter.
DRUGTamoxifen
As per clinical guidelines
DRUGLetrozole
As per clinical guidelines
DRUGExemestane
As per clinical guidelines
DRUGAnastrozole
As per clinical guidelines
Sponsors
Pfizer
AstraZeneca
Institute of Cancer Research, United Kingdom
UNICANCER
Gustave Roussy, Cancer Campus, Grand Paris
Invitae Corporation
Royal Marsden NHS Foundation Trust
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
for ctDNA Surveillance: 1. Written informed consent to participate in the trial and to donation of tissue and blood samples 2. Male or female patients aged 18 years or older 3. ECOG performance status 0, 1 or 2 (see https://ecog-acrin.org/resources/ecog-performance-status) 4. Histologically proven primary ER+ (Allred score 6/8 or greater, or stain in ≥10% of cancer cells) and HER2- (immunohistochemistry 0/1+ and/or negative by in situ hybridization) breast cancer as determined by local laboratory 5. Patients with high risk early stage breast cancer according to at least one of the following criteria: Primary surgery (no other treatment prior to surgery) A. Four or more involved axillary lymph nodes or positive supraclavicular lymph node at diagnosis, or B. Tumour size \> 5 cm, regardless of lymph node status, or C. 1-3 involved axillary lymph nodes and at least one of the following; i) Tumour size \> 3 cm, ii) histological grade 3 iii) high genomic risk defined as Oncotype Dx Recurrence Score \>=26, Prosigna score \>=60, EPclin risk score \>=4.0, or Mammaprint high risk category, or Neoadjuvant chemotherapy (chemotherapy prior to surgery) D. At least one lymph node positive (micrometastasis or macrometastasis) after chemotherapy E. Lymph node negative and tumour size \> 3 cm after chemotherapy Neoadjuvant endocrine therapy (endocrine based therapy prior to surgery) Use the primary surgery criteria - staging tumour size and lymph node status may be either the pathological staging after endocrine therapy or on the initial clinical staging prior to neoadjuvant therapy 6. Available tissue from one archival tumour tissue sample (either from diagnostic biopsy, primary surgery or where available residual disease post-neoadjuvant chemotherapy) 7. No evidence of macroscopic distant metastatic disease or incurable locally advanced disease on staging scans conducted at any time since initial diagnosis. 8. Patients receiving standard endocrine therapy with aromatase inhibitors (letrozole, anastrazole, exemestane), tamoxifen, or combination of such for a minimum of 6 months\* and maximum of 7 years duration with an additional three years of endocrine therapy planned. Pre- or peri-menopausal patients may also receive GnRH analogues. \* patients may enrol during the first 6 months of standard endocrine therapy, and wait until at least 6 months of endocrine therapy has been received prior to starting ctDNA surveillance 9. Patients must have had surgery achieving clear margins (as per local guidelines) 10. Female and male patients of reproductive potential must be willing to use an adequate method of contraception for the first three years of the trial, if randomised to standard endocrine therapy for the duration of trial treatment through to at least 4 weeks after the last dose of trial treatment, and if randomised to fulvestrant and palbociclib to 2 years after the last dose of fulvestrant (see section 4.6). Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient. 11. Patients willing to have frequent blood tests. Inclusion Criteria for Interventional phase: 1. Signed informed consent for treatment 2. ECOG performance status 0, 1 or 2 3. Women of childbearing potential should have a negative serum pregnancy test prior to randomisation. If randomisation occurs more than 72 hours prior to receiving the first dose of treatment the test must be repeated before treatment. 4. Female and male patients of childbearing potential must be willing to use an adequate method of contraception (section 4.6), starting with the first dose of treatment through 4 weeks after the last dose of treatment if randomised to standard endocrine therapy and 2 years after the last dose of fulvestrant if randomised to fulvestrant and palbociclib. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient. Female patients will be deemed not of childbearing potential if they are postmenopausal or have had irreversible sterilisation 5. Patient has adequate bone marrow and organ function as defined by the following laboratory values: 1. Absolute Neutrophil Count (ANC) ≥ 1.5 × 109/L 2. Platelets ≥ 100 × 109/L 3. Haemoglobin ≥ 100 g/L 4. INR ≤1.5 5. Creatinine \<1.5 x ULN and creatinine clearance ≥30ml/min 6. Total bilirubin \< ULN except for patients with Gilbert's syndrome who may only be included if the total bilirubin is ≤ 3.0 × ULN or direct bilirubin ≤ 1.5 × ULN. 7. Alanine aminotransferase (ALT) \< 2.5 x ULN 8. Aspartate aminotransferase (AST) \< 2.5 × ULN 6. Patients must be post-menopausal OR Pre- or peri-menopausal patients or men may be enrolled if they have ovarian/gonadal suppression with licensed GnRH analogues. Patients must have commenced licensed GnRH analogues at least 2 weeks prior to Cycle 1 Day 1 and continue throughout the study if randomised to fulvestrant and palbociclib. Post-menopausal female patients, as defined by at least one of the following: * Age ≥60 years; * Age \<60 years and cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause, and serum estradiol and FSH levels within the institutional laboratory's reference range for post-menopausal females; * Documented bilateral oophorectomy;
Exclusion criteria
for ctDNA Surveillance: 1. Any concurrent or planned treatment for the current diagnosis of breast cancer other than adjuvant endocrine therapy or a bisphosphonate. 2. Patients with prior exposure to a CDK 4/6 inhibitor as part of standard of care may enrol only after at least 12 months from completing CDK4/6 therapy. 3. Prior exposure to therapeutic dose of fulvestrant is not permitted. One subtherapeutic dose of fulvestrant is permitted. 4. Prior diagnosis of cancer including prior diagnosis of breast cancer in the previous 5 years, other than for non-melanoma carcinoma of the skin or cervical carcinoma in situ 5. Patients previously entered into a therapeutic trial where experimental therapy is continued post-surgery. Patients who have entered a clinical trial of a CDK4/6 inhibitor in the adjuvant setting are not eligible. Patients who received a CDK4/6 inhibitor only before an operation, with no post-operative adjuvant use, are eligible. 6. Treatment with an unlicensed or investigational product within 4 weeks prior registration to trial 7. Patient has not recovered to ≤ grade 1 (except alopecia or certain other toxicities, which in the opinion of the Investigator should not exclude the patient) from related side effects of any prior antineoplastic therapy, not including side-effects of endocrine therapy 8. Patient with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral medication (e.g. Crohn's disease, ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome, or small bowel resection) 9. Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator' opinion cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol. 10. Clinically significant uncontrolled heart disease including any of the following: 1. History of myocardial infarction (MI), angina pectoris, symptomatic pericarditis, or coronary artery bypass graft (CABG) within 6 months prior to trial entry 2. Symptomatic congestive heart failure 3. Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome. 4. Cardiac arrhythmia. 11. History of pneumonitis, interstitial lung disease or pulmonary fibrosis 12. Known history of Human Immunodeficiency Virus (HIV) (testing not required as part of study screening) 13. Known active Hepatitis B or Hepatitis C (testing not required as part of study screening) 14. Females who are known to be pregnant or breastfeeding 15. History of bleeding diathesis (i.e. disseminated intravascular coagulation, clotting factor deficiency), other known abnormalities in coagulation or treatment with anticoagulants. Low molecular weight heparin (LMWH), low dose aspirin or clopidogrel are permitted. 16. Child-Pugh class C hepatic impairment or creatinine clearance \< 30ml/min. 17. Patient with bilateral tumours, or unilateral multifocal cancers with multiple separate primary cancers.(Multifocal cancer that reflects a single primary cancer, in the opinion of the investigator, are eligible)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of positive ctDNA result during surveillance (Surveillance phase) | Up to 36 months from entry to study | Test during the surveillance phase detects presence of ctDNA |
| Incidence of positive ctDNA result at first test (Surveillance phase) | Start of study | Test during the surveillance phase detects presence of ctDNA in the first test |
| Relapse free survival (Treatment phase) | 60 months from randomisation | Time from randomization to invasive local/regional recurrence (including ipsilateral invasive breast recurrence) or distant recurrence or death from any cause. Patients with second primary invasive cancers (breast or non-breast) would be censored at time of detection. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency and Severity of adverse events | up to 24 months from randomisation | Frequency and severity of Adverse Events (AEs) assessed as per CTCAE v5 |
| Overall survival | up to 60 months from randomisation | Time from randomisation to death from any cause |
| Invasive disease free survival | up to 60 months from randomisation | Time from randomisation to invasive local/regional recurrence (including ipsilateral invasive breast recurrence), new breast cancer (ipsilateral or contralateral) or distant recurrence or death from any cause. Patients with non-invasive recurrences or second primary invasive cancers (non-breast) would be censored at time of detection. |
| Distant recurrence free survival | up to 60 months from randomisation | Time from randomization to distant invasive breast cancer recurrence or death from any cause. Patients with new contralateral invasive breast cancers or second primary invasive non-breast cancers would be censored at time of detection. |
| EQ-5D-5L quality of life assessment: Mobility element | up to 24 months from randomisation | Assessed using the 5-point scale. |
| EQ-5D-5L quality of life assessment: Self-care element | up to 24 months from randomisation | Assessed using the 5-point scale. |
| EQ-5D-5L quality of life assessment: Usual activities element | up to 24 months from randomisation | Assessed using the 5-point scale. |
| EQ-5D-5L quality of life assessment: Pain/ Discomfort element | up to 24 months from randomisation | Assessed using the 5-point scale. |
| EQ-5D-5L quality of life assessment: Anxiety/ Depression element | up to 24 months from randomisation | Assessed using the 5-point scale. |
| EQ-5D-5L quality of life assessment: Visual Analogue Scale | up to 24 months from randomisation | Assessed using 0-100 scale. |
Countries
France, United Kingdom
Contacts
Primary ContactProject Manager
Outcome results
None listed